Effects of Virtual Reality Environments on Walking in Adults With and Without Knee Osteoarthritis
NCT07920120, Not applicable, Recruiting, University of Primorska
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Virtual Reality Environments on Walking in Adults With and Without Knee Osteoarthritis | ClinicalTrials.gov |
| NCT number | NCT07920120 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Primorska | ClinicalTrials.gov |
| Conditions | Knee Osteoarthritis | ClinicalTrials.gov |
| Interventions | Immersive Virtual Reality Walking Conditions, Non-VR Walking | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Gait Speed | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Mean gait speed (m/s) during overground walking, measured using the Xsens MVN Awinda inertial motion capture system. Gait speed will be calculated as the average across valid walking trials for each of the five experimental conditions (one non-VR and four VR conditions). | ClinicalTrials.gov |
| Secondary | Cadence | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Cadence (steps/min) measured using the Xsens MVN Awinda inertial motion capture system. Mean cadence will be calculated across valid walking trials for each of the five experimental conditions. | ClinicalTrials.gov |
| Secondary | Stride Length | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Mean stride length (m), defined as the distance covered during one complete stride, measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Stride Time | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Mean stride time (s), defined as the duration of one complete gait cycle, measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Step Width | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Mean step width (m), defined as the mediolateral distance between the feet during walking, measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Stance Phase Duration | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Mean stance phase duration, expressed as a percentage of the gait cycle (%), measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Swing Phase Duration | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Mean swing phase duration, expressed as a percentage of the gait cycle (%), measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Double Support Duration | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Mean double support duration, expressed as a percentage of the gait cycle (%), measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | First Vertical Ground Reaction Force Peak | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | First vertical ground reaction force peak during weight acceptance, measured using force platforms, normalized to body weight, and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Second Vertical Ground Reaction Force Peak | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Second vertical ground reaction force peak during push-off, measured using force platforms, normalized to body weight, and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Mid-Stance Minimum Vertical Ground Reaction Force | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Minimum vertical ground reaction force during mid-stance, measured using force platforms, normalized to body weight, and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Hip Sagittal Range of Motion | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Hip flexion-extension range of motion during walking, expressed in degrees, measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Knee Sagittal Range of Motion | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Knee flexion-extension range of motion during walking, expressed in degrees, measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Ankle Sagittal Range of Motion | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Ankle dorsiflexion-plantarflexion range of motion during walking, expressed in degrees, measured using the Xsens MVN Awinda inertial motion capture system and averaged across valid trials in each walking condition. | ClinicalTrials.gov |
| Secondary | Step Time Variability | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Variability in step time during walking, assessed using the Xsens MVN Awinda inertial motion capture system and expressed as the coefficient of variation (%). Variability is calculated across consecutive steps within each experimental condition. | ClinicalTrials.gov |
| Secondary | Stance Time Variability | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Variability in stance phase duration during walking, assessed using the Xsens MVN Awinda inertial motion capture system. Variability is calculated across consecutive gait cycles within each experimental condition. | ClinicalTrials.gov |
| Secondary | Step Width Variability | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Variability in the mediolateral distance between the feet during walking, assessed using the Xsens MVN Awinda inertial motion capture system across consecutive steps within each experimental condition. | ClinicalTrials.gov |
| Secondary | Gait Symmetry Index | Day 1 (during the single experimental session, assessed during each of the five walking conditions). | Left-right symmetry of gait, assessed using inertial motion capture and/or ground reaction force data. The index represents differences between the lower limbs in loading or stance time across experimental conditions. | ClinicalTrials.gov |
| Secondary | Pain Intensity | Day 1 (immediately after each of the five walking conditions during the single experimental session). | Pain intensity is assessed in participants with knee osteoarthritis using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants rate their pain after each of the five walking conditions. | ClinicalTrials.gov |
| Secondary | Perceived Fear and Safety During Walking | Day 1 (immediately after each of the five walking conditions during the single experimental session). | Perceived fear and safety during walking are assessed using a custom questionnaire after each of the five walking conditions in participants with knee osteoarthritis and healthy controls. Perceived fear is rated on a 7-point scale ranging from 1 (no fear at all) to 7 (extreme fear), with higher scores indicating greater fear (a worse outcome). Perceived safety is rated on a separate 7-point scale ranging from 1 (not at all safe) to 7 (completely safe), with higher scores indicating greater perceived safety (a better outcome). The two ratings are reported separately and are not combined into a total score. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)